Inclusion Criteria:

• * Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC)
• * Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2
• * Frequent premature ventricular complexes (PVCs)
• * Implantable cardioverter-defibrillator (ICD) implantation ≥ 12 weeks prior to consent
• * Left ventricular ejection fraction ≥ 50%

Exclusion Criteria:

• * Evidence of variant(s) in addition to PKP2 that meets the standard criteria to be considered pathogenic or likely pathogenic for ACM
• * Other cardiac abnormalities as specified in the protocol
• * New York Heart Association Functional Class III and IV at the time of consent
• * History of prior gene transfer therapy